Search tips
Search criteria 


Logo of ncommsLink to Publisher's site
Nat Commun. 2016; 7: 11904.
Published online 2016 June 17. doi:  10.1038/ncomms11904
PMCID: PMC4915028

Tumour suppressor death-associated protein kinase targets cytoplasmic HIF-1α for Th17 suppression


Death-associated protein kinase (DAPK) is a tumour suppressor. Here we show that DAPK also inhibits T helper 17 (Th17) and prevents Th17-mediated pathology in a mouse model of autoimmunity. We demonstrate that DAPK specifically downregulates hypoxia-inducible factor 1α (HIF-1α). In contrast to the predominant nuclear localization of HIF-1α in many cell types, HIF-1α is located in both the cytoplasm and nucleus in T cells, allowing for a cytosolic DAPK–HIF-1α interaction. DAPK also binds prolyl hydroxylase domain protein 2 (PHD2) and increases HIF-1α-PHD2 association. DAPK thereby promotes the proline hydroxylation and proteasome degradation of HIF-1α. Consequently, DAPK deficiency leads to excess HIF-1α accumulation, enhanced IL-17 expression and exacerbated experimental autoimmune encephalomyelitis. Additional knockout of HIF-1α restores the normal differentiation of Dapk−/− Th17 cells and prevents experimental autoimmune encephalomyelitis development. Our results reveal a mechanism involving DAPK-mediated degradation of cytoplasmic HIF-1α, and suggest that raising DAPK levels could be used for treatment of Th17-associated inflammatory diseases.

Upon activation, the T helper 17 (Th17) subset of immune cells plays critical roles in modulating tissue inflammation and combating microbial infections. However, due to their inflammatory nature, Th17 cells also contribute to autoimmune diseases1,2,3. Experimental autoimmune encephalomyelitis (EAE) is a well-studied mouse model for multiple sclerosis that is also mediated by Th17 (refs 4, 5, 6). Th17 cells differ from the Th1 and Th2 lineages in secretion of interleukin (IL)-17 (refs 7, 8), which induces inflammatory gene expression in target cells and leads to pathogenesis in the EAE model9. Transforming growth factor (TGF)-β is critical for the commitment to the Th17 lineage10,11. TGF-β acts synergistically with the STAT3-activating cytokines, IL-6, IL-21 and IL-23, to promote RORγt expression and Th17 differentiation4,7,12,13,14,15,16. The Th17-specific transcription factor RORγt12 acts together with RORα and STAT3 (ref. 17) to induce full Th17 cell differentiation.

Hypoxia-inducible factor-1α (HIF-1α) is an oxygen tension sensor widely expressed in different cell types, including Th17 cells. In the presence of O2, HIF-1α is hydroxylated at Pro402 and Pro564 by prolyl hydroxylase domain protein 2 (PHD2)/PHD3, followed by ubiquitination by the von Hippel–Lindau (VHL)-containing E3 complex that promotes proteasome degradation18,19,20,21,22. At low oxygen tension, HIF-1α is stabilized by inactivation of PHD2/PHD3 (refs 18, 19, 20, 21, 22). Once stabilized, HIF-1α activates the expression of target genes involved in hypoxic responses. HIF-1α is also upregulated by inflammatory cytokines in normoxic conditions23.

The Hif1a transcript is constitutively expressed in T lymphocytes, and the HIF-1α protein is detected after T-cell receptor (TCR) stimulation under hypoxic conditions24,25. HIF-1α is highly expressed in Th17 cells26,27, priming at physiological oxygen tension in the presence of inflammatory cytokines. HIF-1α plays a prominent role in Th17 cell differentiation26,27 by activating the transcription of Rorc (RORγt), and it helps recruit CBP/p300 to the RORγt transcription complex but does not directly bind to the IL-17 promoter27. Additionally, HIF-1α increases glycolysis by inducing the expression of glycolytic enzymes, which further contributes to Th17 development26,28. HIF-1α also contributes to the survival of Th17 cells by coordination with Notch to enhance Bcl-2 expression29. In contrast, targeted degradation of HIF-1α by miR-210 negatively regulates Th17 differentiation30.

HIF-1α promotes carcinogenesis and is a prominent cancer target18,19. Various HIF-1α inhibitors have been identified and are currently being studied for their efficacy in cancer therapy18,19,31,32. Presumably, HIF-1α inhibitors could also be used for treatment of Th17-mediated inflammatory diseases. However, HIF-1α is essential for oxygen homoeostasis, and curtailment of the protective effects of HIF-1α by HIF-1α inhibitors may limit their application.

Death-associated protein kinase (DAPk/DAPK) is a multi-domain serine/threonine kinase regulated by calcium33,34. DAPK belongs to the DAPK family, which also contains DAPK-related protein 1 and zipper-interacting protein kinase (also called DAPK3), both of which share 80% identity in their kinase domains with DAPK33. The DAPK family also contains two distantly related kinases: DAPK-related apoptosis inducing kinase 1 and 2 (DRK1 and DRK2)35. DAPK family members are pro-apoptotic proteins and function as tumour suppressors, and are specifically downregulated in many types of cancer36,37,38,39,40,41. DAPK participates in a wide variety of cellular events—including apoptosis, autophagy, membrane blebbing and stress fibre formation—that contribute to its tumour suppressor functions. In T lymphocytes, DAPK inhibits T-cell activation by suppressing TCR-induced nuclear factor (NF)-κB activation42. DAPK is induced by TGF-β (ref. 43), and is present in the early precursors of Th17, but the role of DAPK in Th17 immune cells is unclear.

In the present study, we found that DAPK negatively regulates Th17 differentiation. DAPK deficiency leads to preferential Th17 differentiation and exacerbated EAE induction. During the differentiation of Th17, the presence of DAPK is accompanied by downregulation of HIF-1α. We further found that, in contrast to the exclusive nuclear localization of HIF-1α in most other cells, HIF-1α is located in both the cytoplasm and nucleus of T cells, allowing the cytosolic binding of DAPK and subsequent HIF-1α degradation. Our results illustrate a novel mechanism of Th17 regulation by downregulating cytoplasmic HIF-1α, and suggest the therapeutic potential of increasing DAPK levels in Th17-mediated inflammatory diseases.


DAPK inhibits T-cell activation and attenuates EAE

Our previous studies showed that expression of the dominant negative mutant of DAPK, [K42A]DAPK, leads to increased IL-2 production and NF-κB activation in T-cell lines42. Extending these studies, we examined T cells from the Dapk−/− mouse44. T-cell development was not affected by DAPK deficiency, as illustrated by the normal thymic and peripheral T-cell populations in the Dapk−/− mouse (Supplementary Fig. 1a,b). Following TCR stimulation, Dapk−/− T-cell proliferation was enhanced relative to the wild-type (WT) T cells (Supplementary Fig. 2a). This was associated with increased IL-2 and interferon (IFN)-γ production in naive Dapk−/− T cells (Supplementary Fig. 2b). An increase in IL-17 was also observed in Dapk−/− T cells (Supplementary Fig. 2c). In contrast, the production of IL-4 in primary T cells was not affected by DAPK deficiency (Supplementary Fig. 2c). Additionally, IFN-γ production was similar between WT and Dapk−/− T cells when cultured in Th0 conditions (Supplementary Fig. 2d). A prominent increase in NF-κB activation, indicated by the enhanced nuclear translocation of p65 (RelA), was also observed in Dapk−/− T cells stimulated through the TCR (Supplementary Fig. 2e).

We further examined whether the enhanced T-cell activation in Dapk−/− mice led to increased susceptibility to autoimmune diseases, using EAE as our model. After priming with myelin oligodendrocyte glycoprotein (MOG) peptide, disease onset was earlier in Dapk−/− mice than their WT littermates (Fig. 1a). Additionally, the severity of encephalomyelitis was higher in Dapk−/− mice than their WT counterparts. This was correlated with an increase in mononuclear cell infiltration and demyelination in spinal cords from primed Dapk−/− mice (Fig. 1b,c). We also isolated T cells from the primed mice and determined their reactivity towards antigen. Consistent with exacerbated EAE generation, the response to MOG peptide in Dapk−/− T cells was nearly double that of control T cells (Fig. 1d).

Figure 1
DAPK deficiency increases T-cell activation and EAE exacerbation.

We further used transgenic mice with T-cell-specific expression of [ΔCAM]DAPK42, the constitutively active form of DAPK, to analyse EAE induction. T-cell development was normal in [ΔCAM]DAPK-transgenic mice (Supplementary Fig. 3a,b). We increased the dose of MOG peptide for a more profound EAE response in the control mice, allowing us to differentiate any inhibitory effect from the DAPK transgene. The expression of [ΔCAM]DAPK in T cells suppressed EAE generation (Supplementary Fig. 3c). The EAE symptoms were attenuated in [ΔCAM]DAPK-transgenic mice in comparison with WT littermate controls. Reduced responses to MOG peptide were also found for T cells isolated from [ΔCAM]DAPK-transgenic mice (Supplementary Fig. 3d). Together, these results demonstrate that DAPK deficiency enhanced EAE generation, whereas T-cell-specific expression of active DAPK suppressed EAE induction, suggesting that DAPK in T cells negatively regulates EAE pathogenesis.

Both Th17 and Th1 contribute to the development of EAE and multiple sclerosis6. Notably, IL-17 production, but not IFN-γ generation, was increased in MOG-primed Dapk−/− T cells (Fig. 1e), suggesting a preferential expansion of DAPK-deficient Th17 cells. We examined the expression of IFN-γ and IL-17 in mononuclear cells infiltrated into the spinal cords of EAE-induced mice. During the peak of EAE induction, IFN-γ+ cells were more abundant than IL-17+ cells in spinal cords from WT mice (Supplementary Fig. 4a). Conversely, more IL-17+ cells than IFN-γ+ cells were detected in the spinal cords from Dapk−/− mice with encephalomyelitis (Supplementary Fig. 4a). Quantitation shows an increased IL-17+:IFN-γ+ cells ratio in EAE-inducing Dapk−/− mice (Supplementary Fig. 4b).

We further examined the induction of EAE in Rag1−/− mice through adoptive transfer of 2D2 T cells. The adoptive transfer of MOG-specific 2D2 cells that were differentiated into Th17 cells allows for assessment of the effect of DAPK on the induction of antigen-specific and Th17-specific EAE. Dapk−/− 2D2 Th17 cells triggered earlier disease onset and induced more severe encephalomyelitis than WT 2D2 Th17 cells (Fig. 1f). In contrast, the EAE onset and disease severity induced by Dapk−/− 2D2 Th1 cells and WT 2D2 Th1 cells were similar (Fig. 1g). Together, these results suggest that DAPK deficiency leads to an increase in encephalitogenic Th17 cells, but not encephalitogenic Th1 cells.

Preferential Th17 differentiation from Dapk −/− T cells

We found that expression of DAPK was higher in Th17 cells than Th1 cells (Fig. 2a), consistent with the report that DAPK is induced by TGF-β43. Therefore, we examined differentiation of Th1 and Th17 cells from Dapk/− T cells. Naive CD4+ T cells from control and Dapk/− T cells were stimulated by CD3/CD28 in the presence of TGF-β and IL-6 to induce Th17 differentiation. Differentiation into Th17 was significantly increased for Dapk/− T cells, with the IL-17-producing population significantly larger in Dapk/− Th17 cells relative to the WT (Fig. 2b, left panel), as also illustrated by an elevated mean fluorescence intensity (MFI; Fig. 2b, right panel). This was also confirmed by ELISA, which showed a threefold increase in IL-17 secretion by Dapk/− Th17 cells compared with control Th17 cells (Fig. 2c). In addition, for Th17 cells induced by IL-21 and TGF-β, IL-17 production also increased approximately threefold for Dapk/− Th17 cells (Supplementary Fig. 5a). A similar extent of increase in IL-17 expression was found for Dapk/− Th17 cells induced by TGF-β, IL-1β, IL-6 and IL-23 (Supplementary Fig. 5b). However, no effect was found on DAPK deficiency in Th17 cells induced by IL-1β, IL-6 and IL-23 (ref. 45; Supplementary Fig. 5c), suggesting that regulation of Th17 by DAPK depends on priming with TGF-β. In parallel experiments, T-cell-specific transgenic expression of [ΔCAM]DAPK attenuated Th17 differentiation mediated by TGF-β and IL-6 (Fig. 2d,e). Together, these results suggest that DAPK inhibits TGF-β-dependent Th17 development.

Figure 2
Enhanced Th17 development in Dapk−/− T cells.

Elevated RORγt and RORα in Dapk −/− Th17 cells

We then determined whether the increased production of IL-17 correlated with enhanced induction of the transcription of Il17 genes. Quantitative PCR confirmed that the expression of Il17a and Il17f was elevated in DAPK-deficient Th17 cells relative to the WT Th17 cells (Fig. 2f), implying that enhanced IL-17 generation could be partly attributed to increased expression of their mRNAs. Induction of Il21 and Il23r—the cytokine and receptor preferentially expressed in Th17 cells, respectively—were also increased in Dapk/− Th17 cells. In addition, levels of Rorc and Rora—the master transcription factors determining the expression of IL-17—were twofold higher in DAPK-null Th17 cells compared with control Th17 cells (Fig. 2f), which correlated with the elevated protein levels of RORγt in Dapk/− Th17 cells (Fig. 2h). As a control, in the activated Th0 cells, Il17a, Il17f, Il21, Il23r, Rorc and Rora were absent (Fig. 2f). In addition, the expression of Il17a, Il17f, Rorc and Il21 was inhibited in [ΔCAM]DAPK-transgenic Th17 cells (Fig. 2g). Together, these results suggest that DAPK suppresses Th17 differentiation by inhibiting the induction of RORγt and RORα.

In parallel experiments, T cells were primed with IL-12 for Th1 differentiation. Supplementary Fig. 5d illustrates that the development into Th1 cells was comparable between WT and Dapk/− T cells. Consistent with this result, the expression of Tbx21 (T-bet) and Ifng was not affected by the deficiency of DAPK (Supplementary Fig. 5e). Similarly, differentiation into Th1 cells was not altered by the [ΔCAM]DAPK transgene (Supplementary Fig. 5f).

Since DAPK targets Rorc expression, we further examined whether the transcription factors regulating RORγt expression were modulated by DAPK. STAT3 is known to activate the Rorc promoter and promote Th17 cell development12,13,14,15,16,46. Figure 2i demonstrates that the levels of STAT3 were comparable between WT and Dapk−/− T cells. IL-6-triggered STAT3 phosphorylation was also similar between control and Dapk−/− T cells (Fig. 2i). Similarly, IL-21-triggered STAT3 phosphorylation was comparable between WT and Dapk−/− T cells (Supplementary Fig. 5g). Therefore, DAPK deficiency does not appear to interfere with STAT3 expression and activation.

We also determined whether activation of the IL-17 promoter by RORγt and RORα was regulated by DAPK. To exclude interference from endogenous DAPK, DAPK was knocked down in 293T cells by siRNA targets to its 5′UTR (Supplementary Fig. 6a). IL-17P-Luc was activated in 293T cells by co-transfection with RORγt (Supplementary Fig. 6b). Co-expression of RORγt with DAPK, the dominant negative DAPK [K42A]DAPK or [ΔCAM]DAPK all inhibited RORγt-directed Il17 promoter activation. Similarly, RORα-mediated IL-17P-Luc activation was inhibited by co-expression of RORα with DAPK, [K42A]DAPK or [ΔCAM]DAPK (Supplementary Fig. 6c). Therefore, DAPK likely inhibits Th17 development at two sequential stages, that is, expression of both RORγt and RORα as well as RORγt/RORα-mediated IL-17 expression.

DAPK downregulates HIF-1α in Th17 differentiation

It has been previously shown that HIF-1α promotes Th17 differentiation26,27. Consistent with this observation, diminished Th17 differentiation was found in Hif1a−/− T cells (Fig. 3a). HIF-1α is known for its participation in carcinogenesis18,19, while DAPK is a tumour suppressor. Therefore, we investigated whether DAPK directly modulated the expression of HIF-1α. HIF-1α was upregulated in Dapk−/− Th17 cells (Fig. 3b), which correlated with the enhanced IL-17 expression in the knockout T cells. The increased HIF-1α protein in Dapk−/− T cells was not due to an increase in Hif1a mRNA, as Hif1a transcript levels were comparable between WT and Dapk−/− T cells during the course of Th17 differentiation (Fig. 3c). Because HIF-1α expression is regulated by the mTORC1 pathway24,47,48, we examined whether DAPK deficiency affected mTORC1 signalling in T cells. Expression and phosphorylation of mTOR were similar between WT and Dapk−/− Th17 cells (Supplementary Fig. 7a). Further, activation of the mTOR substrates p70 S6 kinase and 4E-BP1 in Th17 cells was not affected by DAPK deficiency (Supplementary Fig. 7a). Similarly, p70 S6 kinase-mediated phosphorylation of ribosomal S6 at S235 and S240 was comparable between WT and Dapk−/− T cells (Supplementary Fig. 7b,c). In addition, overexpression of DAPK downregulated the levels of HIF-1α in normal T cells cultured under hypoxic conditions (Fig. 3d). Together, these results suggest that DAPK targets HIF-1α at the post-transcriptional level.

Figure 3
DAPK promotes HIF-1α degradation and DAPK deficiency increases HIF-1α levels in T cells.

We next examined the effect of DAPK on the stability of HIF-1α. Cycloheximide-induced HIF-1α protein instability was enhanced by the presence of DAPK in 293T cells (Fig. 3e), while HIF-1α protein stability was increased in DAPK-deficient Th17 cells (Fig. 3f), suggesting that DAPK promotes HIF-1α protein destabilization. DAPK-induced HIF-1α protein downregulation was inhibited by MG132 in 293T cells, but not by NH4Cl, leupeptin or chloroquine (Fig. 3g). In addition, MG132 treatment increased HIF-1α to similar levels in WT and Dapk−/− Th17 cells (Fig. 3h). These results suggest the involvement of the proteasome degradation pathway in DAPK-mediated HIF-1α downregulation in Th17 cells.

In a separate experiment, we examined whether HIF-1α protein expression could be induced by prolonged TCR activation in T cells under normoxic conditions (Fig. 3i). CD3-induced HIF-1α protein expression was much higher in Dapk−/− T cells than WT T cells (Fig. 3i), further illustrating the ability of DAPK to downregulate HIF-1α protein.

HIF-1α has also been shown to antagonize Foxp3 and inhibit regulatory T cells (Treg)27,49. The development and in vitro suppressive activity of natural regulatory cells (nTreg) were not affected in Dapk−/− nTregs (Supplementary Fig. 8a,b). However, the differentiation of induced regulatory T cells (iTreg) from CD4+CD25 T cells was moderately impaired in Dapk−/− T cells (Supplementary Fig. 8c). The in vitro suppressive activity of Dapk−/− iTregs was also reduced relative to WT iTregs (Supplementary Fig. 8d).

DAPK interacts with cytoplasmic HIF-1α in T cells

To isolate the mechanism underlying DAPK-dependent HIF-1α degradation, we next examined whether there was a direct interaction between DAPK and HIF-1α. DAPK is a cytosolic protein whereas HIF-1α is known for its predominant nuclear localization, as shown in hypoxic HeLa cells (Fig. 4a). HIF-1α was induced in T cells through prolonged TCR stimulation (Fig. 3i), followed by immunoblotting to determine its localization. Some HIF-1α was present in the cytosolic fraction of activated T cells (Fig. 4b). Similarly, the presence of HIF-1α was detected in the cytoplasmic fraction of Th17 cells (Fig. 4c). The cytosolic localization of HIF-1α in Th17 cells, but not in HeLa cells, was further confirmed by confocal microscopy (Fig. 4d). In addition, DAPK co-localized with HIF-1α in the cytoplasm of hypoxic Jurkat cells (Fig. 4e), as well as in the cytosol of normoxic Th17 and Th0 cells (Fig. 4f).

Figure 4
Cytoplasmic presence of HIF-1α and co-localization with DAPK in T cells.

Since HIF-1α and DAPK co-localized to the cytoplasm, we looked for (and found, see Fig. 4g) their direct interaction by co-immunoprecipitation. The cytoskeleton-binding domain of DAPK was required for the association with HIF-1α (Fig. 4h), while the N-terminal domain of HIF-1α interacted with DAPK (Supplementary Fig. 9a). The association of DAPK with endogenous HIF-1α was also observed in hypoxic T cells (Fig. 4i). Together, these results suggest that DAPK interacts with HIF-1α in the cytosol of T cells, and DAPK may regulate the protein stability of HIF-1α through this direct binding. We also examined whether the kinase domain of DAPK participates in the downregulation of HIF-1α. An N-terminal DAPK fragment containing the kinase domain and ankyrin repeats weakly reduced HIF-1α expression, while a C-terminal DAPK segment from the cytoskeleton binding to death domain effectively promoted HIF-1α degradation (Supplementary Fig. 9b). In addition, we found that HIF-1α is not a kinase substrate of DAPK since recombinant HIF-1α was not phosphorylated by DAPK in vitro (Supplementary Fig. 9c,d). Therefore, even though DAPK binds HIF-1α and induces HIF-1α protein instability, the kinase domain of DAPK appears to be disposable in HIF-1α downregulation.

DAPK induces PHD2-mediated HIF-1α degradation

The inclusion of ubiquitin enhanced the ability of DAPK to downregulate HIF-1α (Supplementary Fig. 10a), illustrating the involvement of the ubiquitin-dependent degradation process. The stability of HIF-1α protein is regulated by proline hydroxylation, a step necessary for its subsequent binding to VHL protein leading to ubiquitination and proteasome degradation18,19,20,22. Therefore, we sought to identify the degradation pathways responsible for DAPK-regulated HIF-1α stability. Deletion of the HIF-1α oxygen-dependent degradation domain containing the proline residues necessary for hydroxylation conferred resistance to DAPK-induced degradation (Fig. 5a). Similarly, inhibition of PHD1/2, which hydroxylates HIF-1α protein, by deferoxamine mesylate (DFX) restored the expression levels of HIF-1α protein in DAPK-expressing T cells and in 293T cells (Fig. 5b; Supplementary Fig. 10b). This result was consistent with the decreased hydroxylation of HIF-1α protein at proline 564 in Dapk−/− T cells (Fig. 5c) and the increased proline 564 hydroxylation in DAPK-overexpressing Jurkat cells (Fig. 5d). Mutation of the hydroxylation sites Pro402 and Pro564 on HIF-1α into alanine (2PA) conferred resistance of HIF-1α protein to DAPK-induced degradation in T cells and in HEK293T cells (Fig. 5e; Supplementary Fig. 10c). We confirmed that DAPK deficiency did not affect the levels of PHD1 and PHD2 in T cells (Fig. 5f). However, knockdown of PHD2 prevented DAPK-induced HIF-1α degradation in T cells (Fig. 5g). Taken together, these results suggest that DAPK-induced HIF-1α downregulation is partly mediated by PHD2-triggered proline hydroxylation on HIF-1α.

Figure 5
DAPK promotes PHD2-dependent HIF-1α degradation.

We further detected an interaction between DAPK and PHD2 in T cells (Fig. 6a). Co-localization of DAPK with PHD2 was observed in Th17 cells by confocal microscopy (Fig. 6b). In addition, PHD2 co-localized with HIF-1α in the nucleus and cytoplasm of Th17 cells (Fig. 6c). We also identified the N-terminal part (aa 1–180) of PHD2 as the DAPK-interacting region (Fig. 6d). Addition of recombinant DAPK protein enhanced the interaction of GST-HIF-1α and FLAG-PHD2 in an in vitro binding assay (Fig. 6e). Therefore, by binding to both HIF-1α and PHD2, a possible role for DAPK is to enhance the association of PHD2 with HIF-1α and increase HIF-1α degradation.

Figure 6
DAPK interacts with PHD2 and increases PHD2-HIF-1α association.

HIF-1α knockout inhibits Dapk −/− Th17 cell differentiation

We hypothesized that if the excess generation of IL-17 in Dapk−/− T cells is due to enhanced HIF-1α-mediated Th17 differentiation, the additional deletion of HIF-1α should reduce IL-17 production to normal levels in Dapk−/− T cells. We generated mice with Dapk−/− Hif1a−/− by crossing mice with T-cell-specific deletion of HIF-1α (Cd4Cre X Hif1af/f) with Dapk−/− mice. Deletion of HIF-1α and/or DAPK in T cells from each genotype was confirmed by immunoblotting (Fig. 7a). In agreement with our hypothesis, we found that while Dapk−/− T cells exhibited enhanced differentiation of naive CD4+ T cells into Th17 cells, Dapk−/− Hif1a−/− T cells displayed levels similar to WT T cells (Fig. 7b). Knockout of HIF-1α also decreased the levels of RORγt in Dapk−/− Th17 cells (Fig. 7c). Therefore, elevated HIF-1α levels partly account for the increased IL-17 expression in Dapk−/− T cells. We further examined whether selective deletion of HIF-1α in T cells attenuated the exacerbated EAE generation in Dapk−/− mice. The severe EAE disease scores in Dapk−/− mice were largely attenuated by T-cell-selective deletion of HIF-1α (Fig. 7d), supporting that DAPK acts upstream of HIF-1α in EAE development. T-cell-specific deletion of HIF-1α did not affect the development and suppressive activity of nTreg in Dapk−/− mice (Supplementary Fig. 11a,b). The reduced development of Dapk−/− iTregs was restored by HIF-1α knockout (Supplementary Fig. 11c), yet the impaired suppressive activity was not corrected in Dapk−/−Hif1a−/− iTregs (Supplementary Fig. 11d). Together, these results suggest that DAPK–HIF-1α interaction contributes little to maintain normal Treg functioning, in contrast to a prominent role of DAPK–HIF-1α antagonism in Th17 cells.

Figure 7
HIF-1α-knockout prevents excess Th17 differentiation in Dapk−/− T cells.


In this study, we identified a negative role of DAPK in Th17 development. In Dapk/− T cells, generation of IL-17A, IL-17F, IL-21 and IL-23R were highly elevated. We further found that the levels of RORγt and RORα—the transcription factors dictating IL-17 expression—were elevated in DAPK-deficient Th17 cells; even though activation of the Rorc inducer STAT3 was similar between WT and Dapk/− T cells (Fig. 2i; Supplementary Fig. 5g). Instead, increases in the expression of RORγt and RORα could be partly attributed to elevated levels of HIF-1α protein. In addition, phosphorylation of mTOR, p70 S6 kinase, 4E-BP1 and ribosomal S6 were comparable between WT and Dapk−/− Th17 cells (Supplementary Fig. 7), suggesting that the increased levels of HIF-1α in Dapk−/− Th17 cells are not caused by increased mTOR signalling. We further found that DAPK promoted the destabilization of HIF-1α protein in a proteasome-dependent manner (Fig. 3).

DAPK expression is induced by TGF-β (ref. 43), which is commonly used for Th17 differentiation10,11. This may partly explain why DAPK levels were higher in Th17 cells than Th1 cells (Fig. 2a). The lower DAPK expression in Th1 cells likely correlated with the weak effect of DAPK deficiency in Th1 cells. Even though naive Dapk−/− T cells displayed increased production of IFN-γ (Supplementary Fig. 2b), IFN-γ expression was not enhanced in re-stimulated DAPK-deficient T cells, including T cells optimized for Th0 and Th1 differentiation (Supplementary Figs 2d and 5d). In addition, IFN-γ production was comparable in MOG-primed T cells from WT and Dapk/− mice (Fig. 1e). Similarly, transgenic expression of DAPK did not affect Th1 development (Supplementary Fig. 5f).

DAPK deficiency led to enhanced sensitivity to EAE induction (Fig. 1a–c). We found that the ratio of IL-17-expressing cells to IFN-γ-expressing cells was significantly increased in spinal cords from Dapk/− mice during peak EAE induction (Supplementary Fig. 4), suggesting enhanced spinal cord infiltration of Dapk/− Th17 cells. We also observed that transfer of Dapk/− 2D2 Th17 cells induced highly exacerbated EAE in comparison to WT Th17 cells (Fig. 1f). DAPK-deficient Th17 cells thus displayed increased encephalitogenic activity relative to WT Th17 cells. In contrast, EAE induction by Dapk/− 2D2 Th1 cells was similar to that induced by WT 2D2 Th1 cells (Fig. 1g). Therefore, DAPK deficiency correlates with preferential induction of pathogenic Th17.

We have previously shown that DAPK specifically suppresses TCR-induced NF-κB activation42, as confirmed here by the elevated RelA nuclear translocation in Dapk−/− T cells (Supplementary Fig. 2e). NF-κB activation in T cells is required for the generation of autoimmune encephalomyelitis; mice deficient in NF-κB1 (p50) are resistant to the induction of EAE50, whereas PKCθ deficiency prevents T-cell activation and the pathogenesis of EAE51. NF-κB has been shown to directly activate the Hif1a promoter52. In the present study, we found that induction of Hif1a transcripts during Th17 differentiation was not affected by Dapk deficiency (Fig. 3c), indicating that enhanced NF-κB activation in Dapk−/− T cells did not lead to a further increase in Hif1a expression. We speculate that the levels of NF-κB activation in WT T cells were already sufficient for optimal transcriptional activation of Hif1a mRNA.

A previous study of DRAK2 showed that deletion of the gene Stk17b2, which encodes DRAK2, results in complete resistance to EAE induction35. DRAK2 knockout is accompanied by increased T-cell activation, similar to Dapk-deficient T cells35. However, TCR-induced NF-κB activation is selectively enhanced in Dapk−/− T cells (Supplementary Fig. 2e), but is attenuated in DRAK2-null T cells35. In addition, DRAK2 consists only of a catalytic domain, lacking the cytoskeleton-binding domain33 by which DAPK interacts with HIF-1α (Fig. 4h). We also found that a DAPK kinase domain fragment was not efficient in promoting HIF-1α degradation (Supplementary Fig. 9b). It is likely that the different roles in EAE induction of DAPK and DRAK2 could be partly attributed to their differential effects on NF-κB activation and HIF-1α downregulation.

A novel finding in the present study is that DAPK interacts with HIF-1α and promotes the degradation of HIF-1α in T cells. We reveal that, in contrast to the predominant nuclear localization of HIF-1α in HeLa cells, HIF-1α protein was present in both the cytoplasm and nucleus of T cells (Fig. 4a–f). The cytosolic location of HIF-1α protein permits direct interaction with, and subsequent destabilization by, DAPK. Therefore, DAPK exhibits an additional ability to regulate HIF-1α protein in T cells by its ability to associate with HIF-1α. We further show that DAPK increased the proline hydroxylation of HIF-1α protein (Fig. 5c,d), and HIF-1α proteins lacking the hydroxylation sites were resistant to DAPK-induced degradation (Fig. 5a,e). Knockdown of PHD2 also eliminated the ability of DAPK to downregulate HIF-1α (Fig. 5g), suggesting that the binding of DAPK to HIF-1α protein leads to proline hydroxylation of HIF-1α and subsequent HIF-1α ubiquitination by VHL.

HIF-1α is pivotal for Th17 differentiation. The specific downregulation of HIF-1α protein by DAPK leads to preferential enhancement of Th17 development in the absence of DAPK-null T cells. This is further supported by the fact that additional HIF-1α knockout eliminated the excess Th17 differentiation and encephalitogenic activity of Dapk/− T cells (Fig. 7). HIF-1α protein is also known to promote Foxp3 degradation and negatively regulates Treg differentiation27,49. Despite that differentiation and functioning of iTreg from Dapk/− T cells were impaired (Supplementary Fig. 8c,d), knockout of HIF-1α did not restore functioning of Dapk/− iTregs (Supplementary Fig. 11d), suggesting a minor role of DAPK–HIF-1α antagonism in Treg cells. Therefore, the ability of DAPK to inhibit HIF-1α predominantly regulates Th17 cells, and impaired Treg function do not seem to contribute to the enhanced Th17 development and severe EAE disease observed in Dapk/− mice. Why Th17 and Tregs display different susceptibility to regulation by the DAPK–HIF-1α interaction is currently being investigated.

Recent studies have revealed that hypoxia promotes the expression of miR-103/107 that target DAPK for downregulation in cancer cells53. HIF-1α induces the expression of KLHL20, which coordinates with Cul3 for ubiquitination and proteasome degradation of DAPK in several cancer cell lines54,55. Together with the results from the present study, we propose a mutual antagonism between HIF-1α and DAPK. We suggest that the continuous cross-interaction between HIF-1α and DAPK, modulated by specific environmental cues, may determine the patho-physiological status of Th17 cells.

DAPK is a tumour suppressor known to be downregulated in many types of cancers36,37,38,39,40,41. Our results illustrate that DAPK is not only a tumour suppressor, but also plays a role in the prevention of Th17-mediated autoimmune diseases like EAE. DAPK suppresses tumour formation and metastasis through its promotion of apoptosis, induction of autophagy and regulation of cell motility56. In the present study, we have demonstrated that DAPK inhibits EAE development by inducing HIF-1α degradation and inhibiting pro-inflammatory Th17 cell differentiation. Notably, HIF-1α is also known for its prominent role in tumorigenesis, with levels of HIF-1α correlating with poor prognoses for various cancer types18,19. Even though HIF-1α is exclusively localized in the nucleus of most cancer cells, it will be interesting to examine whether the ability of DAPK to promote HIF-1α degradation in the cytoplasm also contributes to the tumour suppressing function of DAPK in selective cancer types. We found that HIF-1α was present in the cytoplasm of T-cell leukaemia Jurkat cells and was subjected to DAPK regulation (Figs 4e and and5e),5e), suggesting that DAPK likely exhibits a tumour suppressor effect in T leukaemia cells by directly binding to the cytosolic HIF-1α to prompt HIF-1α downregulation.

Th17 cells contribute to autoimmune diseases—including multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases, psoriasis and autoimmune diabetes1,2,3, and Th17 is a target for immunotherapy in these inflammatory diseases. In addition to promoting Th17 differentiation, HIF-1α contributes to the inflammatory activities of different innate immune cells including macrophages and neutrophils22. Therefore, targeted HIF-1α degradation by DAPK upregulation is a potential novel approach in the treatment of Th17-associated inflammatory diseases.

The critical role of HIF-1α in carcinogenesis and metastases has led to the identification of drugs that inhibit HIF-1α (refs 18, 19, 21, 31, 32). Conceivably, HIF-1α inhibitors are also potential therapeutic agents for HIF-1α-mediated diseases—including pulmonary arterial hypertension, hereditary erythrocytosis, obstructive sleep apnea, ocular neovascularization and traumatic shock19,20—as well as Th17-mediated inflammatory diseases. However, HIF-1α is critical for oxygen homoeostasis, and is protective in coronary artery disease, peripheral artery disease, wound healing, colitis and organ transplantation rejection19,20,21. Thus, the therapeutic benefits of HIF-1α inhibitors are expected to be offset by the loss of HIF-1α-mediated protective responses. In the present study, we used Th17 as an example to demonstrate an alternative approach to downregulating HIF-1α. The cytoplasmic presence of HIF-1α permits its interaction with DAPK in the cytosol of T cells, leading to HIF-1α downregulation. DAPK-induced cytosolic HIF-1α degradation presumably does not operate in cells exhibiting exclusively nuclear HIF-1α, leaving the HIF-1α in those cells unaffected. Compounds that activate DAPK have been identified41, and further improvements in the specificity of drugs for DAPK induction may lead to reagents capable of effectively downregulating HIF-1α in DAPK-dependent processes. These drugs could potentially be used for treatment of Th17-mediated inflammatory diseases and T-cell leukaemia. Future investigations will help validate the therapeutic approach of inhibiting HIF-1α pathogenic activity in T cells through DAPK upregulation, without affecting the HIF-1α in other cells.



Calcium ionophore (A23187), phorbol 12-myristate 13-acetate (TPA), MG132, chloroquine, ammonium chloride (NH4Cl), leupeptin, cycloheximide (CHX), DFX, anti-DAPK (D2178, DAPK-55, western blot (WB) 1:1,000, immunofluorescence (IF) 1:50), anti-HA (H3633, HA-7, WB 1:1,000, immunoprecipitation (IP) 1 μg per test), and anti-FLAG (F1804, M2, WB 1:1,000, IF 1:400) were purchased from Sigma (St Louis, MO, USA). Anti-p70S6K (sc-230, C-18, WB 1:1,000), anti-GAPDH (sc-32233, 6C5, WB 1:10,000), anti-HDAC2 (sc-55541, B-2, WB 1:500) and anti-p65 (sc-372G, C-20, WB 1:1,000) were obtained from Santa Cruz Biotech (Santa Cruz, CA, USA). Anti-RORγt (14–6981, B2D, WB 1:1,000), anti-CD4-PE-Cy7 (25-0041, GK1.5, flow cytometry (FCM) 1:100), anti-CD62L-APC (17–0621, MEL-14, FCM 1:100), recombinant mouse IL-6 (14–8061) and IL-23 (14–8231), anti-CD69-PE (12–0691, H1.2F3, FCM 1:100), anti-Foxp3-APC (50–5773, FJK-16s, FCM 1:100), mouse IL-2 and mouse IFN-γ ELISA kit were purchased from eBioscience (San Diego, CA, USA). STAT3 antibody (GTX15523, WB 1:1,000) was obtained from GeneTex (Irving, CA, USA). Anti-phospho STAT3Y705 (9131, WB 1:1,000), anti-phospho mTORS2448 (2971, WB 1:1,000), anti-phospho p70S6KT389 (9205, WB 1:1,000), anti-phospho 4E-BP1T70 (9455, WB 1:1,000), Alexa 647-conjugated anti-S6S235/236 (4851, D57.2.2E, FCM 1:100), Alexa 647-conjugated anti-S6S240/244 (5044, D68F8, FCM 1:100), anti-mTOR (2972, WB 1:1,000), anti-4E-BP1 (9452, WB 1:1,000), anti-PHD2 (4835, D31E11, WB 1:1,000, IF 1:50), anti-Myc (2276, 9B11, WB 1:1,000, IP 1 μg per test), and anti-hydroxy HIF-1αP564 (3434, D43B5, WB 1:1,000) were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-actin (MAB1501, C4, WB 1:6,000) and anti-tubulin (05–661, AA2, WB 1:6,000) were purchased from Merck Millipore (Billerica, MA, USA). Anti- mouse HIF-1α (10006421, WB 1:1,000, IF 1:100) was purchased from Cayman Chemicals (Ann Arbor, MI, USA). Anti-human HIF-1α (610959, 54/HIF-1α, WB 1:500, IF 1:100), and anti-HSP90 (610419, 68/Hsp90, WB 1:4,000) were obtained from BD-Biosciences (Franklin Lakes, NJ, USA). Anti-CD4-FITC (100501, RM4–5, FCM 1:100), anti-CD8a-PE (100708, 53-6.7, FCM 1:100), anti-CD44-FITC (103006, IM7, FCM 1:100), anti-IL-17A-PE (506904, TC11-18H10.1, FCM 1:100), anti-TCRβ-FITC (109206, H57–597, FCM 1:100), anti-CD25-PE (102008, PC61, FCM 1:100), anti-IFN-γ-APC (505810, XMG1.2, FCM 1:100), anti-IFN-γ (507801, DB-1, IF 1:200), LEAF purified anti-mouse IFN-γ (505707, R4-6A2, cell culture 5 μg ml−1) and LEAF purified anti-mouse IL-4 (504115, 11B11, cell culture 5 μg ml−1) were purchased from BioLegend (San Diego, CA, USA). Anti-PHD1 (ab108980, EPR2745, WB 1:1,000) and anti-IL-17 (ab91649, IF 1:100) were purchased from Abcam (Cambridge, UK). Anti-mouse CD3 (2C11), anti-mouse CD28 (37.51), anti-mouse IL-2, and anti-mouse CD4 (RL172.4) were purified in our laboratory. Recombinant mouse IL-12 and IL-21, mouse IL-17A ELISA kit, and mouse IL-4 ELISA kit were purchased from R&D (Minneapolis, MN, USA). Recombinant mouse IL-2 and human TGF-β were purchased from PeproTech (Rocky Hill, NJ, USA). Anti-HIF-1α (A300-286A, IP 1 μg per test) was purchased from Bethyl Laboratories (Montgomery, TX, USA). Mouse anti-Lamin B1 (33–2000, L-5, WB 1:1,000), Alexa Flour488-labelled goat anti-mouse IgG (A11001, IF 1:500), Alexa Flour555-labelled goat anti-mouse IgG (A21422, IF 1:500), Alexa Flour488-labelled goat anti-rabbit IgG (A11034, IF 1:500) and Alexa Flour555-labelled goat anti-rabbit IgG (A21428, IF 1:500) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). siRNA control (siCtrl), siRNAs specific for PHD2 (EGLN1 siRNA SMARTpool) and for human DAPK (siDAPK) were purchased from GE Dharmacon (Lafayette, CO, USA). The sequence of siDAPK is: UCU GGG AAG CGG AGC UGA AUU.

Cell cultures

HEK293T (ATCC CRL-3216), HeLa (ATCC CCL-2) and Jurkat T lymphoma (clone E6-1, ATCC TIB-152) were obtained from ATCC. Cell lines were examined for mycoplasma contamination using Mycoplasma Detection Kit (R&D). Normal T cells and Jurkat cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum (Invitrogen Life Technology), 10 mM glutamine, 100 U ml−1 penicillin, 100 μg ml−1 streptomycin, and 50 μM 2-ME (complete RPMI medium). HEK293T and HeLa cells were cultured in DMEM medium with the same supplements as in complete RPMI medium. For hypoxia (1% O2) experiments, T cells were cultured in the cell incubator containing an oxygen controller ProOx-110 (BioSpherix) using gas of 5% CO2 and 95% N2 to reduce the oxygen content. Expression of DAPK or its mutants was performed by transfection of T cells with DAPK, [K42A]DAPK, or [ΔCAM]DAPK through electroporation using the MP-100 system (Life Technologies).


Production of Dapk−/− mice44 and p37.1-[ΔCAM]DAPK-transgenic mice42 (both in a C57BL/6 background) were previously described. B6.129-Hif1atm3Rsjo/J (Hif1af/f) mice57, Rag1−/− mice (in C57BL/6 background), and C57BL/6-Tg(Tcra2D2, Tcrb2D2)1Kuch/J (2D2 TCRMOG) transgenic mice58 were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Cd4-Cre mice (in C57BL/6 background) were purchased from Taconic Farms (Hudson, NY, USA). Mice were maintained in the SPF mouse facility of the Institute of Molecular Biology, Academia Sinica. All mouse experiments were performed using 8–16-week-old mice. For in vivo experiments, sex-matched male and female mice were used. Donor and recipient mice were also sex-matched in T cells transfer assay. Because mouse experiments are limited by the availability of the knockout mice and their littermate control, no randomization was used. Mouse experiments were not blinded. All mouse experiments were conducted with approval from the Institutional Animal Care & Utilization Committee, Academia Sinica.

Induction of T-helper cells and iTregs

Mouse T cells were isolated from spleen and peripheral lymph nodes by negative selection using an anti-mouse Ig panning method. Total CD4+ T cells were purified by positive selection using a rat anti-mouse CD4 antibody (RL172.4) panning method. Naive CD4 T cells (CD4+CD25CD44lowCD62Lhigh) were then sorted by FACSVantage SE (BD Bioscience). Naive CD4 T cells were then activated by 2 μg ml−1 plate-bound anti-CD3 (2C11) plus 1 μg ml−1 anti-CD28 (37.51). IL-2 (20 U ml−1) was added for Th0 differentiation; IL-12 (10 ng ml−1), IL-2 (5 ng ml−1) and anti-IL-4 (10 μg ml−1) were added to induce Th1 development; and TGF-β (2 ng ml−1), IL-6 (2 ng ml−1), anti-IL-2 (5 μg ml−1), anti-IL-4 (5 μg ml−1) and anti-IFN-γ (5 μg ml−1) were added to induce Th17 differentiation. Th17 cells were also induced by replacing IL-6 with IL-21 (100 ng ml−1) in the same mixture. After 3-to-5 days, Th1 and Th17 cells were re-stimulated with anti-CD3/CD28 or TPA/A23187. For intracellular staining, monensin (2 nM) was added 1 h after activation, and intracellular content of IL-17 and IFN-γ was determined after another 3 h. For mRNA expression, cells were harvested 3 h after TPA/A23187 stimulation and RNA was prepared. For ELISA, cell culture supernatants were collected 24 h after TPA/A23187 activation. Induced Treg (iTreg) cells were generated from CD4+CD25 T cells and activated by IL-2 (20 ng ml−1), TGF-β (5 ng ml−1), and plate-bound anti-CD3 (2 μg ml−1) plus anti-CD28 (1 μg ml−1) for 1-to-5 days.

EAE induction

DAPK[ΔCAM]-transgenic, DAPK-knockout, and their WT littermate control mice were immunized subcutaneously with 200 μg of MOG peptide 35–55 (Kelowna, Taipei, Taiwan) emulsified in CFA containing 400 μg Mycobacterium tuberculosis (Sigma), followed by intraperitoneal injection of 200 ng pertussis toxin (List Labs, Campbell, CA, USA) at day 0 and day 2. Mice were monitored daily for clinical signs and then clinically scored by the following criteria: 0, no syndrome; 1, limp tail; 1.5, tail paralysis and waddling gait; 2, weak tail and partial hind limb paralysis; 2.5, paralysis of one hind limb; 3, total hind limb paralysis; 3.5, complete hind limb and partial fore limb paralysis; 4, moribund state; 5, complete paralysis and death. Numbers of mice used in EAE experiments were based on those used in documented EAE studies27,59,60,61.

EAE induced by adoptive transfer of 2D2 T cells was performed according to the protocol of Jäger et al.59. Naive T cells from 2D2 or 2D2 Dapk−/− mice were differentiated into Th17 cells by incubation with MOG35-55 peptide (20 μg ml−1), hTGF-β (3 ng ml−1), mIL-6 (20 ng ml−1), anti-IL-4 (5 μg ml−1), anti-IFN-γ (5 μg ml−1) and threefold γ-irradiated T-cell-depleted splenic cells. IL-23 (10 ng ml−1) was added 48 h after differentiation. Five days after initial Th17 differentiation, Th17 cells were re-stimulated with plate-bound anti-CD3/anti-CD28 (2 μg ml−1each) in the absence of exogenous cytokines for 48 h. 2D2 or 2D2 Dapk−/− naïve T cells were differentiated into Th1 by incubation with MOG35-55 peptide (20 μg ml−1), mIL-12 (10 ng ml−1), anti-IL-4 (10 μg ml−1) and threefold γ-irradiated T-cell-depleted splenic cells for 5 days. Th17 and Th1 cells were washed three times with cold PBS, and 5 × 106 Th17 cells or 3 × 106 Th1 cells were transferred intravenously into each Rag1−/− mouse. Recipient mice were injected i.p. with 200 ng of pertussis toxin at day 0 and day 2 after T cells transfer. The classical EAE scores were described as above. The non-classical (atypical) EAE was scored by the following criteria60: 0, no syndrome; 1, head turned slightly (ataxia, no tail paralysis); 2, head-turn more pronounced; 3, inability to walk in a straight line; 4, laying on side and rolling continuously unless supported; 5, death. Half scores were given (i.e., 1.5, 2.5) when the clinical phenotype was deemed to lie between two defined criteria.

Histology on spinal cord sections

Mice were perfused with phosphate buffer saline (PBS) followed by 4% (v/v) paraformaldehyde (PFA) in PBS. Spinal cords were isolated and fixed with 4% (v/v) PFA in PBS overnight at 4 °C. Spinal cords were dehydrated with 30% sucrose in PBS for 48 h at 4 °C. Spinal cords were embedded in optimal cutting temperature compound and serial cryosections (30 μM thick) were acquired. Tissue sections were stained with hematoxylin & eosin or luxol fast blue. Images were obtained on a Zeiss Axio Imager Z1 microscope (Jena, Germany) with an objective lens of plan-Apochromat 10 × /0.45 M27 and the camera of Axiocam 506. The channel was TL Brightfield and the depth of focus was at 5.43 μM.

For staining with anti-IFNγ and anti-IL-17, PFA-fixed optimal cutting temperature-embedded sections were pretreated with sodium citrate buffer (pH 6.0, 10 mM sodium citrate, 0.05% Tween-20) at 55 °C for 30 min for antigen retrieval. Sections were washed and permeabilized with 0.3% (v/v) Triton X-100 in PBS at room temperature for 30 min. Sections were incubated in blocking buffer (1% BSA, 0.3% Triton X-100 in PBS) at room temperature for 30 min. Sections were then incubated with primary antibodies diluted in blocking buffer for 48 h at 4 °C. The primary antibodies were anti-IL-17 (Abcam, ab91649, 1:100 dilution) and anti-IFNγ (BioLegend, DB-1, 1:200 dilution). Sections were washed and incubated with Alexa Flour 488 or 555 secondary antibodies (Invitrogen, 1:500 dilution) at room temperature for 2 h. Samples were then washed and mounted with DAPI Fluoromount-G buffer (SouthernBiotech, Birmingham, AL, USA).

Quantitative PCR

T cells were harvested at the time indicated and total RNA was isolated using Trizol (Invitrogen). cDNAs were prepared and analysed for the expression of the gene of interest by real-time PCR using a SYBR-Green PCR master mix kit (Roche). The expression of each gene was normalized to the expression of β-actin. The sequences of the primers were: Rorc, forward, 5′-CGG AGT TTT CCT TTG GGTG-3′ and reverse, 5′-CCG AGG TAT CTC AGT CAC GAA-3′; Rora, forward, 5′-GAA CAC CTT GCC CAG AAC AT-3′ and reverse, 5′-AGC TGC CAC ATC ACC TCT CT-3′; Il17a, forward, 5′-CTC ACA CGA GGC ACA AG-3′ and reverse, 5′-CTC AGC AGC AGC AAC AG-3′; Il17f, forward, 5′-GGG AAG AAG CAG CCA TTG-3′ and reverse, 5′-TCC AGG GGA GGA CAG TT-3′; Il21, forward, 5′-AAA CTC AAG CCA TCA AAC CC-3′ and reverse, 5′-GGT GTC CTT TTC TCA TAC GAA TC-3′; Il23r, forward, 5′-GCA GGA AGT ATT TGG TAT GGG -3′ and reverse, 5′-GAA ATG ATG GAC GCA GAA GG-3′; Actb, forward, 5′-GCC CCC CTG AAC CCT AA-3′ and reverse, 5′-GAC AGC ACA GCC TGG AT-3′; Tbx21, forward, 5′-CGT GGA GGT GAA TGA TGG-3′ and reverse, 5′-GTG ATC TCT GCG TTC TGG TAG-3′; Ifng, forward, 5′-ATC AGC AAC AAC ATA AGC GT-3′ and reverse, 5′-GAC CTC AAA CTT GGC AAT ACTC-3′; Hif1a, forward, 5′-CGG CGA GAA CGA GAA GAA-3′ and reverse, 5′-GCA ACT GAT GAG CAA GCT CATA-3′.

Nuclear extract preparation

Cells were harvested and lysed in cytoplasmic extract (CE) buffer (10 mM Tris-HCl PH7.4, 10 mM NaCl and 3 mM MgCl2) containing 0.1% (primary T cells) or 0.2% NP-40 (for HeLa cells) for 4 min on ice. Cell lysates were centrifuged at 5,000 r.p.m. for 3 min and the supernatants obtained represented cytoplasmic extracts. Pellets were washed and lysed with RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Sodium deoxycholate, 150 mM NaCl and 1 mM EDTA). The supernatants obtained after centrifuging at 13,200 r.p.m. for 10 min represented the nuclear extracts.

Western blot

Cell lysates or immunoprecipitates were resolved by SDS–PAGE and were transferred to PVDF membrane (Millipore) using transfer buffer (30 mM Tris, 250 mM glycine, 1 mM EDTA, 20% methanol) at 4 °C for 2 h at 400 mA. The membrane was treated with block buffer (5% non-fat milk in 0.1% TBST (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Tween-20)) at room temperature for 1 h. The membrane was then incubated with primary antibodies overnight at 4 °C, followed by horseradish peroxidase-conjugated secondary antibodies in blocking buffer at room temperature for 1.5 h. The membrane was developed using ECL western blotting detection kit (GE Healthcare), and the chemiluminescence detected by X-ray film. Western blot images have been cropped for presentation. Full size images are presented in Supplementary Figs 12–17.

Regulatory T cells

nTregs and iTregs (CD4+CD25+) were purified by FACS sorting. For in vitro suppressive assays, CD4+CD25 cells (Teff) were placed into round-bottom 96-well plates at 4 × 104 cells per well (for nTreg) or 1 × 105 cells per well (for iTreg), together with anti-CD3 (1 μg ml−1), 3 × 105 γ-irradiated autologous presenting cells, and different ratios of Treg cells. Cells were incubated for 72 h, and the incorporation of [3H]thymidine was determined.

Intracellular localization of DAPK and HIF-1α/PHD2

Cells were fixed with 4% (v/v) PFA in PBS, and permeabilized with 0.1% (v/v) Triton X-100. The fixed cells were incubated with blocking buffer (5% BSA in PBS) at room temperature for 1 h, followed by primary antibodies in blocking buffer overnight at 4 °C. The primary antibodies were anti-FLAG (Sigma, 1:400), anti-Myc (Cell Signaling, 1:400), anti-human HIF-1α (BD-Biosciences, 1:100), anti-mouse HIF-1α (Cayman Chemicals, 1:100), anti-DAPK (Sigma, 1:50) and anti-PHD2 (Cell Signaling, 1:50). Cells were washed and incubated with Alexa Flour-labelled secondary antibodies, and were then mounted in DAPI Fluoromount-G buffer (SouthernBiotech, Birmingham, AL, USA). Confocal images were obtained with a Zeiss LSM 780 confocal microscope (Jena, Germany) with an objective lens of Plan-Apochromat 63 × /1.4 Oil DIC M27 at room temperature. DAPI-bound DNA was excited at 405 nm and collected at 420 to 475 nm. Alexa Fluor 488 dye was excited at 488 nm and collected at 500 to 550 nm. Alexa Fluor 555 dye was excited at 555 nm and collected at 568 to 629 nm. The pinhole was at 53 μm, with a 9.8 μm section.

Retroviral infection

DAPK cDNA was cloned into retroviral vector GFP-RV and then transfected into HEK293T cells. Retroviruses were isolated from the culture supernatants of the transfected HEK293T cells by centrifugation at 26,000 r.p.m. for 2 h at 4 °C on a Beckman SW28 rotor. The viruses were resuspended in PBS containing 5% BSA overnight at 4 °C and stored at −80 °C. Purified WT CD4+ T cells were activated with plate-bound anti-CD3 (2 μg ml−1) and anti-CD28 (1 μg ml−1) with the addition of IL-2 (100 U ml−1) for 48 h. Activated T cells were infected with retrovirus in the presence of 8 μg ml−1 polybrene by spinning at 2,000 r.p.m. for 1 h at room temperature. Infected T cells were cultured in complete RPMI medium with IL-2 (100 U ml−1) for 48 h. GFP+ cells were sorted by FACSVantage SE, and were cultured in complete RPMI medium plus IL-2 (100 U ml−1) for 2 days before hypoxic treatment.

In vitro binding assays

pGEX-4T3-HIF-1α (GST-HIF-1α) was transformed in BL21 (DE3) Escherichia coli, and recombinant GST-HIF-1α fusion proteins purified on a glutathione Sepharose 4B column. RK5F-DAPK (DAPK-FLAG) and pcDNA4-PHD2 (FLAG-PHD2) were transfected into HEK293T cells. Transfected cells were collected and lysed with WCE buffer (25 mM pH 7.7 HEPEs, 300 mM NaCl, 0.1% Triton X-100, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1 mM Na3VO4, 50 mM NaF and 0.5 mM DTT). Recombinant FLAG fusion proteins were purified with anti-FLAG M2 agarose. Purified recombinant proteins were incubated in PBS at 4 °C for 4 h, and then incubated with anti-GST antibody overnight at 4 °C. Samples were incubated with protein G magnetic beads (GE) at 4 °C for 1 h. The immune complexes were washed with WCE buffer and examined by western blot.

DAPK kinase assay

DAPK kinase assays were performed as previously described62. DAPK proteins were isolated by anti-FLAG from SF21 insect cells and incubated with 5 μg GST-HIF-1α or GST-MLC in kinase reaction buffer (50 mM HEPES pH 7.5, 8 mM MgCl2, 2 mM MnCl2, 0.5 mM CaCl2, 0.1 mg ml−1 bovine serum albumin (BSA), 1 μM bovine CaM (Sigma), 50 μM ATP, 10 μCi [γ-32P]ATP) at 25 °C for 15 min. The reactions were stopped by adding SDS sample buffer, and resolved on SDS–PAGE. The phosphorylation was detected by autoradiography.


Our data were randomly collected but were not blinded. We did not exclude any data in this study. Our data mostly meet the assumption of the tests (normal distribution). Microsoft Office Excel and Prism 5.0 (GraphPad software) were used for data analysis. Unpaired two-tailed Student t-tests were used to compare results from between two groups. Data were presented as mean with standard deviation (s.d.) or standard error of the mean (s.e.m.), as indicated in the figure legend.

Data availability

All relevant data are available from the authors upon request.

Additional information

How to cite this article: Chou, T.-F. et al. Tumour suppressor death-associated protein kinase targets cytoplasmic HIF-1α for Th17 suppression. Nat. Commun. 7:11904 doi: 10.1038/ncomms11904 (2016).

Supplementary Material

Supplementary Information:

Supplementary Figures 1-17


We thank Dr Tzyy-Nan Huang for spinal cord sections, Dr Ching-Yen Tsai of the Transgenic Core, Yamin Lin of the FACS Core and Shu-Hui Huang of the Confocal Core of the Institute of Molecular Biology, Academia Sinica for transgenic mouse generation, cell sorting and confocal microscopy, and Dr John O'Brien for editing the manuscript. This work was supported by grant MOST103-2321-B-001-031 from the Ministry of Science and Technology, and an Academia Sinica Investigator Award from Academia Sinica, Taiwan, R.O.C.


Author contributions T.-F.C., Y.-T.C, W.-C.H, P.-Y.C., H.-Y.L., and S.-T.M. performed experiments, T.-S.H., S.-C.M., R.-H.C., A.K. contributed to generation of key materials and constructs, and M.-Z.L. conceived of, designed and supervised the research and wrote the manuscript.


  • Korn T., Bettelli E., Oukka M. & Kuchroo V. K. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485–517 (2009). [PubMed]
  • Littman D. R. & Rudensky A. Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 845–858 (2010). [PubMed]
  • Weaver C. T., Elson C. O., Fouser L. A. & Kolls J. K. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu. Rev. Pathol. 8, 477–512 (2013). [PMC free article] [PubMed]
  • Langrish C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233–240 (2005). [PMC free article] [PubMed]
  • Kroenke M. A., Carlson T. J., Andjelkovic A. V. & Segal B. M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205, 1535–1541 (2008). [PMC free article] [PubMed]
  • Stromnes I. M., Cerretti L. M., Liggitt D., Harris R. A. & Goverman J. M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 14, 337–342 (2008). [PMC free article] [PubMed]
  • Harrington L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123–1132 (2005). [PubMed]
  • Park H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133–1141 (2005). [PMC free article] [PubMed]
  • Zepp J., Wu L. & Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 32, 232–239 (2011). [PMC free article] [PubMed]
  • Bettelli E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006). [PubMed]
  • Mangan P. R. et al. Transforming growth factor-β induces development of the TH17 lineage. Nature 441, 231–234 (2006). [PubMed]
  • Ivanov I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121–1133 (2006). [PubMed]
  • Yang X. O. et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J. Biol. Chem. 282, 9358–9363 (2007). [PubMed]
  • Korn T. et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448, 484–487 (2007). [PMC free article] [PubMed]
  • Nurieva R. et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448, 480–483 (2007). [PubMed]
  • Gaffen S. L., Jain R., Garg A. V. & Cua D. J. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14, 585–600 (2014). [PMC free article] [PubMed]
  • Yang X. O. et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28, 29–39 (2008). [PMC free article] [PubMed]
  • Keith B., Johnson R. S. & Simon M. C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9–22 (2011). [PMC free article] [PubMed]
  • Semenza G. L. Hypoxia-inducible factors in physiology and medicine. Cell 148, 399–408 (2012). [PMC free article] [PubMed]
  • Semenza G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. Mech. Dis. 9, 41–74 (2014). [PubMed]
  • Eltzschig H. K., Bratton D. L. & Golgan S. P. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat. Rev. Drug Discov. 13, 852–869 (2014). [PMC free article] [PubMed]
  • Palazon A., Goldrath A. W., Nizet V. & Johnson R. S. HIF transcription factors, inflammation, and immunity. Immunity 41, 518–528 (2014). [PMC free article] [PubMed]
  • Hellwig-Burgel T., Rutkowski K., Metzen E., Fandrey J. & Jelkmann W. Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1. Blood 94, 1561–1567 (1999). [PubMed]
  • Nakamura H. et al. TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J. Immunol. 174, 7592–7599 (2005). [PubMed]
  • Makino Y. et al. Hypoxia-inducible factor regulates survival of antigen receptor driven T cells. J. Immunol. 171, 6534–6540 (2003). [PubMed]
  • Shi L. Z. et al. HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367–1376 (2011). [PMC free article] [PubMed]
  • Dang E. V. et al. Control of Th17/Treg balance by hypoxia-inducible factor 1. Cell 146, 772–784 (2011). [PMC free article] [PubMed]
  • Pollizzi K. N. & Powell J. D. Integrating canonical and metabolic signaling programmes in the regulation of T cell responses. Nat. Rev. Immunol. 14, 435–446 (2014). [PMC free article] [PubMed]
  • Kryczek I. et al. Human TH17 cells are long-lived effector memory cells. Sci. Transl. Med. 3, 104ra100 (2011). [PMC free article] [PubMed]
  • Wang H. et al. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat. Immunol. 15, 393–401 (2014). [PMC free article] [PubMed]
  • Jones D. T. & Harris A. L. Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions. Expert Opin. Ther. Targets 16, 463–480 (2012). [PubMed]
  • Xia Y., Choi H. K. & Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur. J. Med. Chem. 49, 24–40 (2012). [PubMed]
  • Bialik S. & Kimchi A. The death-associated protein kinases: structure, function, and beyond. Annu. Rev. Biochem. 75, 189–210 (2006). [PubMed]
  • Shiloh R., Bialik S. & Kimchi A. The DAPK family: a structure-function analysis. Apoptosis 19, 286–297 (2014). [PubMed]
  • McGargill M. A., Wen B. G., Walsh C. M. & Hedrick S. M. A deficiency in Drak2 results in a T cell hypersensitivity and an unexpected resistance to autoimmunity. Immunity 21, 781–791 (2004). [PMC free article] [PubMed]
  • Inbal B. et al. DAP kinase links the control of apoptosis to metastasis. Nature 390, 180–184 (1997). [PubMed]
  • Gozuacik D. & Kimchi A. DAPk protein family and cancer. Autophagy 2, 74–79 (2006). [PubMed]
  • Michie A. M., McCaig A. M., Nakagawa R. & Vukovic M. Death-associated protein kinase (DAPK) and signal transduction: regulation in cancer. FEBS J. 277, 74–80 (2010). [PubMed]
  • Brognard J., Zhang Y. W., Puto L. A. & Hunter T. Cancer associated loss-of-function mutations implicate DAPK3 as a tumor-suppressing kinase. Cancer Res. 71, 3152–3161 (2011). [PMC free article] [PubMed]
  • Humbert M. et al. The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL. J. Leukoc. Biol. 95, 83–93 (2014). [PubMed]
  • Huang Y., Chen L., Guo L., Hupp T. R. & Lin Y. Evaluating DAPK as a therapeutic target. Apoptosis 19, 371–386 (2014). [PubMed]
  • Chuang Y. T., Fang L. W., Lin-Feng M. H., Chen R. H. & Lai M. Z. The tumor suppressor death associated protein kinase targets to TCR-stimulated NF-κB activation. J. Immunol. 180, 3238–3249 (2008). [PubMed]
  • Jang C. W. et al. TGF-β induces apoptosis through Smad-mediated expression of DAP-kinase. Nat. Cell Biol. 4, 51–58 (2002). [PubMed]
  • Gozuacik D. et al. DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death. Cell Death Differ. 15, 1875–1886 (2008). [PubMed]
  • Ghoreschi K. et al. Generation of pathogenic TH17 cells in the absence of TGF-β signalling. Nature 467, 967–971 (2010). [PMC free article] [PubMed]
  • Laurence A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371–381 (2007). [PubMed]
  • Delgoffe G. M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832–844 (2009). [PMC free article] [PubMed]
  • Delgoffe G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295–303 (2011). [PMC free article] [PubMed]
  • Darce J. et al. An N-terminal mutation of the Foxp3 transcription factor alleviates arthritis but exacerbates diabetes. Immunity 36, 731–741 (2012). [PMC free article] [PubMed]
  • Hilliard B., Samoilova E. B., Liu T. S., Rostami A. & Chen Y. Experimental autoimmune encephalomyelitis in NF-κB-deficient mice: roles of NF-κB in the activation and differentiation of autoreactive T cells. J. Immunol. 163, 2937–2943 (1999). [PubMed]
  • Anderson K. et al. Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases. Autoimmunity 39, 469–478 (2006). [PubMed]
  • Rius J. et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453, 807–811 (2008). [PMC free article] [PubMed]
  • Chen H. Y. et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 72, 3631–3641 (2012). [PubMed]
  • Lee Y. R. et al. The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. EMBO J. 29, 1748–1761 (2010). [PubMed]
  • Yuan W. C. et al. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell 20, 214–228 (2011). [PubMed]
  • Chen H. Y., Lee Y. R. & Chen R. H. The functions and regulations of DAPK in cancer metastasis. Apoptosis 19, 364–370 (2014). [PubMed]
  • Ryan H. E. et al. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60, 4010–4015 (2000). [PubMed]
  • Bettelli E. et al. Myelinoligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 197, 1073–1081 (2003). [PMC free article] [PubMed]
  • Jäger A., Dardalhon V., Sobel R. A., Bettelli E. & Kuchroo V. K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 183, 7169–7177 (2009). [PMC free article] [PubMed]
  • Domingues H. S., Mues M., Lassmann H., Wekerle H. & Krishnamoorthy G. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS ONE 5, e15531 (2010). [PMC free article] [PubMed]
  • Rothhammer V. et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J. Exp. Med. 208, 2465–2476 (2011). [PMC free article] [PubMed]
  • Kuo J. C., Lin J. R., Staddon J. M., Hosoya H. & Chen R. H. Uncoordinated regulation of stress fibers and focal adhesions by DAP kinase. J. Cell Sci. 116, 4777–4790 (2003). [PubMed]

Articles from Nature Communications are provided here courtesy of Nature Publishing Group